Irradiation and postangioplasty restenosis - A recent overview

被引:7
|
作者
Ishiwata, S [1 ]
Robinson, K [1 ]
Chronos, N [1 ]
Crocker, IR [1 ]
King, SB [1 ]
机构
[1] Toranomon Hosp, Ctr Cardiovasc, Minato Ku, Tokyo 1058470, Japan
来源
JAPANESE HEART JOURNAL | 2000年 / 41卷 / 05期
关键词
brachytherapy; restenosis; review;
D O I
10.1536/jhj.41.541
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One of the most intriguing developments in recent years towards prevention of restenosis after angioplasty is the use of ionizing radiation. The background for the use of radiation treatment for this application is sound, since radiation is used not only to treat malignant cancerous growths but also is used for treatment of benign hyperplastic disorders such as post-surgical keloid fort-nation and recurrence of pterygium after surgical removal. Restenosis can be considered a form of overexuberant wound healing triggered by angioplasty. Ionizing radiation inhibits serum-stimulated proliferation of many cell types including fibroblasts and smooth muscle cells in vitro and also suppresses the synthesis of collagen by cultured fibroblasts. Liermann who showed inhibition of post-stent restenosis first used ionizing radiation for restenosis prevention clinically in iliac and iliofemoral arteries. Subsequently, extensive animal studies in various restenosis models have shown a profuund inhibitory effect or catheter-based radiation (endovascular brachytherapy) on neointima formation and overall vessel shrinkage (negative remodeling). Based on these results clinical trials have been initiated with several types of devices and isotopes. Among these are Ir-192, P-32, Y-90, Sr-90/Y and Re-188. Additionally, radioactive stents have been developed; devices for clinical use are made radioactive at the mu Ci level by surface implantation of 32P ions. Results from early clinical trials are encouraging and brachytherapy appears safe for clinical use and at an appropriate dose, may be highly effective for restenosis prevention.
引用
收藏
页码:541 / 570
页数:30
相关论文
共 50 条
  • [1] Plasma lipoprotein (a) concentration and postangioplasty restenosis
    Bussiere, JL
    deBourayne, J
    Monsegu, J
    Corbe, H
    Berville, JD
    Lancelin, B
    Ricordel, I
    Ollivier, JP
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1996, 89 (04): : 425 - 429
  • [2] CALCIUM-ANTAGONISTS AND PREVENTION OF POSTANGIOPLASTY RESTENOSIS
    HOBERG, E
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1995, 88 : 29 - 34
  • [3] Possible prevention of postangioplasty restenosis by ascorbic acid
    Tomoda, H
    Yoshitake, M
    Morimoto, K
    Aoki, N
    AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (11): : 1284 - &
  • [4] P2 receptors in atherosclerosis and postangioplasty restenosis
    Seye, Cheikh I.
    Kong, Qiongman
    Yu, Ningpu
    Gonzalez, Fernando A.
    Erb, Laurie
    Weisman, Gary A.
    PURINERGIC SIGNALLING, 2007, 3 (1-2) : 153 - 162
  • [6] Postangioplasty restenosis: a practical model in the porcine carotid artery
    Caramori, PRA
    Eggers, EE
    SilvaFilho, APF
    Uchoa, DM
    Jung, F
    Zago, AC
    Cerski, CTS
    Schwartsmann, G
    Zago, AJ
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1997, 30 (09) : 1087 - 1091
  • [7] Spontaneous regression of postangioplasty restenosis in common iliac artery
    Hirai, T
    Korogi, Y
    Nakashima, K
    Takahashi, M
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 166 (03) : 728 - 729
  • [8] Mechanisms by which vascular brachytherapy prevents postangioplasty restenosis
    Wilcox, JN
    RADIATION THERAPY OF BENIGN DISEASES: CURRENT INDICATIONS AND TECHNIQUES, 2001, 35 : 172 - 191
  • [9] P2 receptors in atherosclerosis and postangioplasty restenosis
    Cheikh I. Seye
    Qiongman Kong
    Ningpu Yu
    Fernando A. Gonzalez
    Laurie Erb
    Gary A. Weisman
    Purinergic Signalling, 2007, 3 : 153 - 162
  • [10] Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis
    Suzuki, T
    Ishiwata, S
    Hasegawa, K
    Yamamoto, K
    Yamazaki, T
    HEART, 2000, 83 (05) : 578 - 578